Skip to content
Menu

Pyxis Oncology, Inc. PYXS

Full chart Compare
Set alert

Price alert · PYXS

All alert types
1.58 USD 0.00 (+0.00%)

Regular-session close

1.66 +0.08 +5.06%

Pre-market · Nov 16, 7:22 AM ET

1.52 Day range 1.60
1.03 52-week range 5.55
YTD
+37.39%
1 year
-64.73%
Market cap
188.98M
Revenue (ttm)
16.15M
EPS (ttm)
-1.27
Shares out
59.47M
Forward P/E
-1.40
YTD return
+37.39%
1-year return
-64.73%
Volume
359.90K
Avg volume
990.53K
Open
1.57
Previous close
1.58
Day's range
1.52 – 1.60
52-week range
1.03 – 5.55
Beta
1.28
Analysts
Strong Buy
Price target
10.00 (+532.9%)

5D -0.09 (-5.39%)

1.501.601.70FriMonTueWedThu1.58

Key statistics

Enterprise value
-23.78M
PEG ratio
0.00
Price / sales
6.15
Price / book
0.65
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-30.08M
Total cash
144.82M
Total debt
20.54M
Return on equity
-39.34%
Short % of float
12.43%
50-day average
2.96
200-day average
3.68

Fundamental scorecard

5 of 25 checks passed on PYXS’s reported financials

Value: 0/5ValueGrowth: 2/5GrowthProfitability: 0/5ProfitabilityFinancial health: 3/5HealthDividend: 0/5Dividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PYXS Revenue — quarterly 0
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PYXS Net income — quarterly -19.98M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PYXS EPS — quarterly -0.24
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PYXS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.32-0.35-0.03-9.38%
Aug 14, 2024Jun 1, 2024-0.33———
Aug 14, 2024Jun 1, 2024-0.33-0.29+0.04+12.12%
May 14, 2024Mar 1, 2024-0.27-0.06+0.21+77.78%
May 14, 2024Mar 1, 2024-0.27———
Mar 21, 2024Dec 1, 2023-0.49———

Upgrades / downgrades

PYXS analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024HC Wainwright & Co.reitBuyBuy
Dec 20, 2024RBC CapitalreitOutperformOutperform
Nov 21, 2024RBC CapitalmainOutperformOutperform
Nov 21, 2024William BlairdownOutperformMarket Perform
Nov 21, 2024HC Wainwright & Co.reitBuyBuy
Nov 8, 2024Stephens & Co.init—Overweight

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PYXS — it syncs with the Stock Master app.

Insider holders

PYXS insider holders
InsiderRelationLatest transactionDateShares held
CIVIK THOMASDirectorStock Award(Grant)Mar 23, 2023221,886
CLINE DARREN SDirectorStock Award(Grant)Mar 25, 2024251,405
CONNEALY PAMELA ANNChief Operating OfficerPurchaseNov 25, 20240
DUPONT JAKOBDirectorStock Award(Grant)Mar 25, 202438,741
FLAVIN JOHN L.DirectorStock Award(Grant)Mar 25, 2024413,015
HUMPHREY RACHEL W M.D.DirectorStock Award(Grant)Mar 25, 202496,805

Institution ownership

PYXS institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp7.04%4,184,1006.99MSep 29, 2024
Laurion Capital Management, LP6.10%3,625,9746.06MSep 29, 2024
Blackrock Inc.4.98%2,964,1604.95MSep 29, 2024
Vanguard Group Inc4.09%2,432,9534.06MSep 29, 2024
Millennium Management Llc3.21%1,906,9783.18MSep 29, 2024
Blue Owl Capital Holdings LP1.89%1,126,0251.88MSep 29, 2024

Fund ownership

PYXS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.18%1,294,6892.16MSep 29, 2024
iShares Russell 2000 ETF2.07%1,231,4722.06MOct 30, 2024
Vanguard Extended Market Index Fund1.32%782,8841.31MSep 29, 2024
abrdn Healthcare Investors1.05%626,6371.05MSep 29, 2024
Fidelity Small Cap Index Fund0.84%500,435835.73KAug 30, 2024
iShares Russell 2000 Value ETF0.83%492,033821.70KOct 30, 2024